Walter Alfredo Goycochea-Valdivia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Walter Alfredo Goycochea-Valdivia has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Olaf Neth
Sección de Infectología e Inmunopatología, Unidad de Pediatría, Hospital Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
4 shared publications Elena Montecatine-Alonso
Department of Pharmacy, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocío, Sevilla, Spain
3 shared publicationsMaría-Victoria Gil-Navarro
Department of Pharmacy, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocío, Sevilla, Spain
3 shared publicationsAna Belén Jiménez Jiménez
Infectología Pediátrica, Servicio de Pediatría, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
2 shared publicationsAntonio José Conejo Fernández
Servicio de Pediatría, Hospital Vithas Xanit, Benalmádena, Málaga, Spain
2 shared publicationsCarlos Rodrigo Gonzalo de Liria
Servicio de Pediatría, Hospital Universitario Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, Spain
2 shared publications
Latest Publications
- 10 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review
Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic with activity against Gram-positive bacteria and is approved for the treatment of acute bacterial skin and skin structure infections. Its pharmacokinetic profile and tolerability make it an attractive option for pediatric infections requiring prolonged therapy, including off-label indications. Methods: A systematic review of the literature was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to evaluate the safety and effectiveness of dalbavancin in pediatric patients. Studies published between 2010 and 2025 were identified through searches of PubMed, Scopus and Web of Science. Clinical trials, pharmacokinetic studies, systematic reviews and case series were included. In addition, a retrospective observational study of pediatric patients treated with dalbavancin at a tertiary hospital between 2023 and 2025 was performed. Results: Ten studies met inclusion criteria, including clinical trials, pharmacokinetic analyses and pediatric case series. Seven patients (age range 5–17 years) were included in the institutional case series, most with significant comorbidities. Infections treated included osteoarticular infections, endocarditis or septic thrombophlebitis, and catheter- or device-related infections. Dalbavancin was primarily prescribed to shorten intravenous therapy, improve adherence and facilitate early discharge. All patients achieved clinical cure without relapse during follow-up, and no adverse events attributable to dalbavancin were observed. Conclusions: Dalbavancin was well tolerated and was associated with favorable outcomes in selected pediatric patients with severe Gram-positive infections, supporting its potential role in facilitating early discharge and outpatient management. Prospective multicenter studies are needed to better define its safety and effectiveness beyond acute bacterial skin and skin structure infections.
- 10 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review
Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic with activity against Gram-positive bacteria and is approved for the treatment of acute bacterial skin and skin structure infections. Its pharmacokinetic profile and tolerability make it an attractive option for pediatric infections requiring prolonged therapy, including off-label indications. Methods: A systematic review of the literature was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to evaluate the safety and effectiveness of dalbavancin in pediatric patients. Studies published between 2010 and 2025 were identified through searches of PubMed, Scopus and Web of Science. Clinical trials, pharmacokinetic studies, systematic reviews and case series were included. In addition, a retrospective observational study of pediatric patients treated with dalbavancin at a tertiary hospital between 2023 and 2025 was performed. Results: Ten studies met inclusion criteria, including clinical trials, pharmacokinetic analyses and pediatric case series. Seven patients (age range 5–17 years) were included in the institutional case series, most with significant comorbidities. Infections treated included osteoarticular infections, endocarditis or septic thrombophlebitis, and catheter- or device-related infections. Dalbavancin was primarily prescribed to shorten intravenous therapy, improve adherence and facilitate early discharge. All patients achieved clinical cure without relapse during follow-up, and no adverse events attributable to dalbavancin were observed. Conclusions: Dalbavancin was well tolerated and was associated with favorable outcomes in selected pediatric patients with severe Gram-positive infections, supporting its potential role in facilitating early discharge and outpatient management. Prospective multicenter studies are needed to better define its safety and effectiveness beyond acute bacterial skin and skin structure infections.
- 5 May 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (8) , e316-e319
Lack of Clinical Response Despite Appropriate Antibiotic Therapy in Pediatrics: Looking Beyond Resistance With the BARNS Model
- 5 May 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (8) , e316-e319
Lack of Clinical Response Despite Appropriate Antibiotic Therapy in Pediatrics: Looking Beyond Resistance With the BARNS Model
- Open Access
- 9 July 2024
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 101 (1) , 46-57
Position statement of the Spanish Society of Paediatric Infectious diseases on the diagnosis and treatment of Mycoplasma pneumoniae infection
- 9 July 2024
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 101 (1) , 46-57
Open AccessPosition statement of the Spanish Society of Paediatric Infectious diseases on the diagnosis and treatment of Mycoplasma pneumoniae infection
- Open Access
- 19 June 2024
- Published by Elsevier in Anales de Pediatría
- Vol. 101 (1) , 46-57
Posicionamiento de la Sociedad Española de Infectología Pediátrica sobre el diagnóstico y tratamiento de la infección por Mycoplasma pneumoniae
- 19 June 2024
- Published by Elsevier in Anales de Pediatría
- Vol. 101 (1) , 46-57
Open AccessPosicionamiento de la Sociedad Española de Infectología Pediátrica sobre el diagnóstico y tratamiento de la infección por Mycoplasma pneumoniae
- Open Access
- 1 January 2023
- Published by GRAPHIMEDIC SA DE CV in Revista Latinoamericana de Infectología Pediátrica
- Vol. 36 (4) , 155-160
¿Por qué necesitamos más investigación traslacional en pediatría?, la historia de la inmunización frente al virus respiratorio sincitial
- 1 January 2023
- Published by GRAPHIMEDIC SA DE CV in Revista Latinoamericana de Infectología Pediátrica
- Vol. 36 (4) , 155-160
Open Access¿Por qué necesitamos más investigación traslacional en pediatría?, la historia de la inmunización frente al virus respiratorio sincitial
- Open Access
- 13 October 2022
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 97 (5) , 351.e1-351.e12
Position statement of the Spanish Society of Paediatric Infectious Diseases on the introduction, implementation and assessment of antimicrobial stewardship programmes in paediatric hospitals
- 13 October 2022
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 97 (5) , 351.e1-351.e12
Open AccessPosition statement of the Spanish Society of Paediatric Infectious Diseases on the introduction, implementation and assessment of antimicrobial stewardship programmes in paediatric hospitals
- 14 September 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (11) , 3889-3898
Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity
The presence of active viral infections has an impact on the prognosis of patients undergoing hematopoietic stem cell transplantation (HSCT). Nevertheless, the number of reports of cytomegalovirus infection in patients with inborn errors of immunity (IEI) who undergo HSCT is relatively low. To analyze the effect of cytomegalovirus infection acquired prior to curative treatment on patient survival in 123 children with IEI. An observational and retrospective study was performed with patients younger than 18 years diagnosed with IEI who were candidates for HSCT, gene therapy, or thymus transplantation at five hospitals in Spain between 2008 and 2019. We included 123 children, 25 infected by cytomegalovirus prior to undergoing curative treatment (20.3%). At IEI diagnosis, 24 of the patients were already infected, 21 of whom had symptomatic cytomegalovirus disease (87%), while the other three patients developed disease before undergoing curative treatment. The patients with cytomegalovirus infection had higher mortality than those without (p = 0.006). Fourteen patients developed refractory cytomegalovirus infection (56%), all of whom died, while no patients with non-refractory infection died (p = 0.001) All deaths that occurred before curative treatment and three of the five after the treatment were attributed to cytomegalovirus. Patients with refractory cytomegalovirus disease had the highest pre-HSCT mortality rate (64.3%), compared with the non-infected children and those with non-refractory cytomegalovirus disease (10.1%) (p < 0.0001). Conclusion: Prevention and prompt control of cytomegalovirus infection, together with early HSCT/gene therapy, are crucial for improving the prognosis in children with IEI. What is Known: • Cytomegalovirus is the most frequent viral infection in children with inborn errors of immunity who are candidates to hematopoietic stem cell transplantation (HSCT). • Active viral infections at the time of HSCT lead to worse prognosis. What is New: • In children with inborn errors of immunity and indication of HSCT, refractory cytomegalovirus disease is associated with a very high mortality rate, compared with non-infected children and those with non-refractory cytomegalovirus disease. • In patients with novel transplantation indications, the presence and treatment response of CMV infection should be considered to decide the best possible moment for HSCT.
- 14 September 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (11) , 3889-3898
Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity
The presence of active viral infections has an impact on the prognosis of patients undergoing hematopoietic stem cell transplantation (HSCT). Nevertheless, the number of reports of cytomegalovirus infection in patients with inborn errors of immunity (IEI) who undergo HSCT is relatively low. To analyze the effect of cytomegalovirus infection acquired prior to curative treatment on patient survival in 123 children with IEI. An observational and retrospective study was performed with patients younger than 18 years diagnosed with IEI who were candidates for HSCT, gene therapy, or thymus transplantation at five hospitals in Spain between 2008 and 2019. We included 123 children, 25 infected by cytomegalovirus prior to undergoing curative treatment (20.3%). At IEI diagnosis, 24 of the patients were already infected, 21 of whom had symptomatic cytomegalovirus disease (87%), while the other three patients developed disease before undergoing curative treatment. The patients with cytomegalovirus infection had higher mortality than those without (p = 0.006). Fourteen patients developed refractory cytomegalovirus infection (56%), all of whom died, while no patients with non-refractory infection died (p = 0.001) All deaths that occurred before curative treatment and three of the five after the treatment were attributed to cytomegalovirus. Patients with refractory cytomegalovirus disease had the highest pre-HSCT mortality rate (64.3%), compared with the non-infected children and those with non-refractory cytomegalovirus disease (10.1%) (p < 0.0001). Conclusion: Prevention and prompt control of cytomegalovirus infection, together with early HSCT/gene therapy, are crucial for improving the prognosis in children with IEI. What is Known: • Cytomegalovirus is the most frequent viral infection in children with inborn errors of immunity who are candidates to hematopoietic stem cell transplantation (HSCT). • Active viral infections at the time of HSCT lead to worse prognosis. What is New: • In children with inborn errors of immunity and indication of HSCT, refractory cytomegalovirus disease is associated with a very high mortality rate, compared with non-infected children and those with non-refractory cytomegalovirus disease. • In patients with novel transplantation indications, the presence and treatment response of CMV infection should be considered to decide the best possible moment for HSCT.
- 1 January 2022
- Published by GRAPHIMEDIC SA DE CV in Revista Latinoamericana de Infectología Pediátrica
- Vol. 35 (2) , 60-63
Tratamiento antibiótico de la infección por Clostridioides difficile en niños: nuevas evidencias y perspectivas futuras
- 1 January 2022
- Published by GRAPHIMEDIC SA DE CV in Revista Latinoamericana de Infectología Pediátrica
- Vol. 35 (2) , 60-63
Tratamiento antibiótico de la infección por Clostridioides difficile en niños: nuevas evidencias y perspectivas futuras
- Open Access
- 1 November 2019
- Published by Elsevier in Anales de Pediatría
- Vol. 91 (5) , 351.e1-351.e13
Documento de posicionamiento de la Asociación Española de Pediatría-Sociedad Española de Infectología Pediátrica (AEP-SEIP) sobre el tratamiento de las infecciones por bacterias multirresistentes
- 1 November 2019
- Published by Elsevier in Anales de Pediatría
- Vol. 91 (5) , 351.e1-351.e13
Open AccessDocumento de posicionamiento de la Asociación Española de Pediatría-Sociedad Española de Infectología Pediátrica (AEP-SEIP) sobre el tratamiento de las infecciones por bacterias multirresistentes
- 1 May 2019
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 37 (5) , 357-358
In reply to: “Antimicrobial defined daily dose adjusted by weight: A proposal for antibiotic consumption measurement in children”
- 1 May 2019
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 37 (5) , 357-358
In reply to: “Antimicrobial defined daily dose adjusted by weight: A proposal for antibiotic consumption measurement in children”